Author

K. Juerchott

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

A. A. Kuehl· 1 shared A. Petersen· 1 shared B. Sawitzki· 1 shared C. Appelt· 1 shared C. Gille· 1 shared C. Iwert· 1 shared C. Meisel· 1 shared C. Scharler· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. A. Kuehl

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

TCAIM controls effector T cell generation by preventing Mitochondria-Endoplasmic Reticulum Contact Site-initiated Cholesterol Biosynthesis

C. Iwert, J. Stein, C. Appelt, K. Vogt, R. J. Rainer, K. Tummler, K. Muehle, K. Stanko, J. Schumann, D. Uebe, K. Juerchott, J. Lisec, K. Janek, C. Gille, K. Textoris-Taube, , B. Sawitzki

This study shows TCAIM prevents effector T cell differentiation by inhibiting mitochondria-ER contact sites that drive cholesterol biosynthesis and HIF1 activation.

bioRxiv · Apr 20, 2021 · PreprintImmunology

Extra-hematopoietic immunomodulatory role of the SCID-susceptibility gene DOCK-2 identified by stepwise maturation of human iPSCs into clonogenic mesodermal stromal progenitors

C. Scharler, R. Poupardin, P. Peking, M. Wolf, G. Brachtl, L. Daheron, K. Schallmoser, K. Juerchott, H. Stachelscheid, H.-D. Volk, D. STRUNK

This study identifies DOCK-2's role in stromal immunomodulation through iPSC differentiation and CRISPR knockout, showing reduced immunomodulatory capacity in DOCK-2-deficient cells.

bioRxiv · Jul 7, 2020 · PreprintImmunology